This approach seeks to achieve a synergistic effect by combining immunotherapy to enhance the immune system’s targeting of cancer cells, encorafenib to inhibit the cancer-driving BRAF V600E mutation, and cetuximab to target the often overactivated EGFR pathway in colorectal cancer. The gene discussed is BRAF; the disease is cancer.